(Q74604118)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

title

Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

R L Basser

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

R Abraham

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

L B To

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

R M Fox

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

M D Green

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

publication date

1 January 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

page(s)

53-58

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. 10-year pathologic and clinical prognostic discriminants

12 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Management and survival of female breast cancer: results of a national survey by the American College of Surgeons

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Strategies for prevention of anthracycline cardiotoxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Conventional versus high-dose epidoxorubicin as single agent in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Outcome of clinical congestive heart failure induced by anthracycline chemotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Doxorubicin-induced congestive heart failure in adults

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008390203340

7 January 2021

Identifiers

DOI

10.1023/A:1008390203340

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10076722%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference